I'm curious here, because you're saying that the real barriers to access to this program are a lack of an ability to use TRIPS flexibilities due to capacity, knowledge, and domestic policy or legislative framework and a funding gap. These are all things that I thought CIDA was supposed to do. Say, for example, an eligible country comes forward and says we have a huge HIV/AIDS epidemic, or we have a malaria epidemic, and we need assistance. Who is the champion in Canada? I just wonder whether or not CIDA is actively engaged in advocacy in Canada.
In this room right now we have a whole lot of government relations specialists for Canadian brand name and generic pharmaceutical companies. I don't think there are very many of the least developed or developing countries that have a whole lot of capacity in Canada to get this whole access regime in motion. Is that CIDA's role? Have you done it, and would you be prepared to apply specific funding envelopes for specific applications, by specific countries, to get this process in motion?